Poolbeg Pharma PLC Ordinary Shares POLB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- GBX7.35
- Day Range
- GBX7.18–7.18
- 52-Week Range
- GBX3.30–9.30
- Bid/Ask
- GBX0.00 / GBX0.00
- Shares Outstanding
- 763.44M
- Market Cap
- GBX5.48B
- Volume/Avg
- 1M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.01%
Company Profile
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.poolbegpharma.com
Valuation
|
Metric
|
POLB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 7.72 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
POLB
|
|---|---|
Quick Ratio | 12.44 |
Current Ratio | 12.44 |
Interest Coverage | — |
Quick Ratio
POLB
Profitability
|
Metric
|
POLB
|
|---|---|
Return on Assets (Normalized) | −52.82% |
Return on Equity (Normalized) | −57.10% |
Return on Invested Capital (Normalized) | −59.54% |
Return on Assets
POLB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|$mFv&!b | LOCK|J?#B | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|G&!rky | LOCK|k!C&n | $76B | |||
| Moderna Inc
MRNA
| LOCK|$<v@<b | LOCK|@Q@ | $75B | |||
| argenx SE ADR
ARGX
| LOCK|%Bpc<Lq | LOCK|&% | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|TrvQvm | LOCK|&> | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|PQ!pj& | LOCK|$RyC | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|xP^H^@q | LOCK|m@VL! | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|S^^<Q^ | LOCK|d^z | $24B | |||
| Incyte Corp
INCY
| LOCK|Gd&h#< | LOCK|&c | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|YfcQh%? | LOCK|gj | $15B |
United States